Merck & Company, Inc. vs Sarepta Therapeutics, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
SRPT
Sarepta Therapeutics, Inc.
$21.49
▲ 2.92%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 4.4/10

Q·Score Breakdown

6.7
Neutral
Overall
4.4
Bearish
6.2
Quality
1.3
7
Health
6.9
6.2
Growth
3.3
7.2
Valuation
6.7
7.1
Sentiment
4.7
MRK

Forward P/E of 11.5× is low relative to sector peers.

SRPT

Healthy balance sheet and financial position.

currently unprofitable (-32% margin).

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
HOLD
Target $21.78 (+1.4%)
23 analysts

Fundamentals

MRK
SRPT
31.5×
Trailing P/E
11.5×
Forward P/E
7.2×
13.6%
Profit Margin
-32.5%
76.6%
Gross Margin
-7.4%
ROE
-53.5%
4.9%
Revenue Growth
-32.7%
Earnings Growth
0.28
Beta
0.28
Price / Book
$277.0B
Market Cap
$2.3B
$73 – $125
52-Week Range
$10 – $65

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →